Gilead Sciences (GILD) Raises Quarterly Dividend 9.3% to $0.47; 1.9% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Gilead Sciences (GILD) PT Lowered to $118 at UBS
April 29, 2016 8:27 AM EDTUBS analyst Marc Goodman lowered his price target on Gilead Sciences (NASDAQ: GILD) to $118.00 (from $130.00) following Q1 results but maintained a Buy rating.
Goddman commented, "We have lowered our HCV sales estimates to reflect lower ASPs (higher rebates to defend share from Merck's... More
Gilead Sciences (GILD) Receives Positive CHMP Opinion for Marketing Odefsey as HIV-1 Treatment
April 29, 2016 8:11 AM EDTOn 28 April 2016 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Odefsey, intended for the treatment of adults and adolescents infected with human immunodeficiency virus 1 (HIV 1). The applicant for this medicinal product is Gilead Sciences International Ltd. (Nasdaq: GILD).
Odefsey is a fixed-dose combination of three active substances,... More
Gilead Sciences (GILD) Needs M&A to Fill the Gap Following HCV Miss - BMO Capital
April 29, 2016 7:40 AM EDTBMO Capital analyst M. Ian Somaiya lowered his price target on Gilead Sciences (NASDAQ: GILD) to $97.00 (from $102.00) following the HCV miss. The firm maintained a Market Perform rating, saying it increases the need for pipeline.
Somaiya commented, "Gilead reported 1Q16 EPS... More
Maxim Group Downgrades Gilead Sciences (GILD) to Hold
April 29, 2016 7:06 AM EDTMaxim Group downgraded Gilead Sciences (NASDAQ: GILD) from Buy to Hold.
Analyst Jason Kolbert highlighted:
Gilead reported quarterly results with total top-line revenues of $7.6B missing consensus of $7.7B by a hair. Non-GAAP quarterly net income was $4.3B or $3.03 per diluted share. The company ended the period with $21.3B in cash and $22B in debt.HCV revenues continue to drive Gilead but tough comps, the laws of growth (for big numbers), and... More